



ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 91/03990	4/1991	WO				
	WO 91/10424	7/1991	WO				
	WO 93/16176	8/1993	WO				
	WO 94/11032	5/1994	WO				
	WO 94/21309	9/1994	WO				
	WO 96/37165	11/1996	WO				
	WO 96/39821	12/1996	WO				
	WO 97/16544	5/1997	WO				
	WO 97/34935	9/1997	WO				
	WO 99/08717	2/1999	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Eliasz R, Wallach D, Kost J, Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor, Cytokine, 1996, Jun; 8(6): 482-7.
	Flemmig TF, Weinacht S, Rudiger S, Rumetsch M, Jung A, Klaiber B, Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid, J Chin Periodontol 1996 OCT; 23 (10):914-21.
	Folkman J, How the field of controlled-release technology began, and its central role in the development of angiogenesis research, Biomaterials, 1990, Nov; 11 (9): 615-8.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 99/16907	4/1999	WO				
	WO 99/43688	9/1999	WO				
	WO 99/47129	9/1999	WO				
	WO 99/47176	9/1999	WO				
	WO 99/64086	12/1999	WO				
	WO 00/12163	3/2000	WO				
	WO 00/40593	7/2000	WO				
	WO 00/55396	9/2000	WO				
	WO 01/21326	3/2001	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Friling R, Yassar Y, Levy R, Kost J, Schwartz B, Mikhailowsky R, Lamprecht SA, A role of transforming growth factor-beta 1 in the control of corneal neovascularization, In Vivo 10, 59-64 (1996).
	Goodson JM, Hogan PE, Dunham SL, Clinical responses following periodontal treatment by local drug delivery, J Periodontal 1985 Nov; 56 (11 Suppl): 81-7.
	Huland E, Falk B, Hubner D, Huland H, In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors, Int. J. Cancer, 1995, 62, 605-9.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/36008	5/2001	WO				
	WO 01/44174	6/2001	WO				
	WO 01/66161	9/2001	WO				
	WO 01/87342	11/2001	WO				
	WO 01/87372	11/2001	WO				
	WO 01/87373	11/2001	WO				
	WO 01/87374	11/2001	WO				
	WO 01/87375	11/2001	WO				
	WO 01/87376	11/2001	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lees VC, Fan TP, West DC, Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan, Lab Invest, 1995, 73, 259-66.
	Lesser GJ, Grossman SA, Leong KW, et al., In vitro and in vivo studies of subcutaneous hydromorphone implants designed for the treatment of cancer pain, Pain, 1996, May-Jun; 65 (2-3): 265-72.
	Lopez JJ, Edelman ER, Stamler A, et al., Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia, Am J Physiol 1998 Mar; 274 (3 Pt 2): H930.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
				APPLICANT Chudzik et al.			
				FILING 21 November 2001		GROUP 1762	

OIPE
 DEC 13 2004
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/26139	4/2002	WO				
	WO 02/26271	4/2002	WO				
	WO 02/26281	4/2002	WO				
	WO 03/022323	3/2003	WO				
	WO 03/064015	8/2003	WO				
	WO 04/000267	12/2003	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Ozaki H, Hayashi H, Vinorel SA, Moromizato Y, Campochiaro PA, Oshima K, Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates, Exp Eye Res, 1997, 64, 505-17.
	Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M, Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia, Surgery 1996 Aug; 120 (2): 182-8.
	Suzuki, T. et al. Stent-based delivery of sirolimus release. Circulation 2001; 104: 1188-1193.

EXAMINER 	DATE CONSIDERED
---------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)






	Jafari, F, et al Point Counterpoint: Drug Eluting Stent Euphoria NOT A PUBLICATION
	Morice et al, A Randomized Comparison of a Sirolimus-Eluting Stent, N Engl J Med, 2002 June; 346, 1773-1780
	Raman et al, Coated Stents: Local Pharmacology, Semin Intervent Cardiol 1998; 3: 133-137
EXAMINER	DATE CONSIDERED

EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


 <p>INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p>				ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
				APPLICANT Chudzik et al.			
				FILING 21 November 2001		GROUP 1762	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	Whelan et al, Mechanisms of Drug Loading and Release Kinetics, Semin Intervent Cardiol 1998; 3: 127-131
	Klugherz et al, Twenty-eight-day Efficacy and Pharmacokinetics, Coronary Artery Disease 2002 13 (3)
	Regar et al, Stent Development and Local Drug Delivery, British Med Bulletin 2001; 59: 227-48
EXAMINER 	DATE CONSIDERED 

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Serruys et al., Rapamycin Eluting Stent: the Onset of a New Era in Interventional Cardiology, Heart 2002 (87) 305-307

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.